Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Trading 04-23 13:19:19 EDT

10.80

+0.38

+3.65%

High10.94	Low10.58	Vol3.56M
Open10.62	D1 Closing10.42	Amplitude3.50%
Mkt Cap7.71B	Tradable Cap4.00B	Total Shares713.55M
T/O38.51M	T/O Rate0.96%	Tradable Shares370.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":10.8,"timestamp":1745428756704,"preClose":10.42,"halted":0,"volume":3561110,"delay":0,"floatShares":370552084,"shares":713549458,"eps":-0.155667,"marketStatus":"Trading","change":0.38,"latestTime":"04-23 13:19:19 EDT","open":10.62,"high":10.94,"low":10.575,"amount":38507023.140879996,"amplitude":0.035029,"askPrice":10.81,"askSize":734,"bidPrice":10.8,"bidSize":964,"shortable":3,"etf":0,"ttmEps":-0.155667,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":10.42,"preHourTrading":{"tag":"盘前","latestPrice":10.59,"preClose":10.42,"latestTime":"09:29 EDT","volume":106,"amount":1122.54,"timestamp":1745414948059},"postHourTrading":{"tag":"盘后","latestPrice":10.45,"preClose":10.42,"latestTime":"18:57 EDT","volume":107143,"amount":1116443,"timestamp":1745362627125},"volumeRatio":1.21318,"impliedVol":0.0829,"impliedVolPercentile":0.036},"requestUrl":"/m/hq/s/ROIV/wiki","defaultTab":"wiki","newsList":[{"id":"2529336626","title":"Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529336626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529336626?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 01:49","pubTimestamp":1745257740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 13:49 ET (17:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2529803909","title":"Immunovant Names New CEO, CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803909","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803909?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 20:12","pubTimestamp":1745237540,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) said Monday it appointed director Eric Venker as chief executive, succeeding Pete Salzmann, who has retired.The company also named Tiago Girao as chief financial officer, succeeding ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT","BK4139","ROIV","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"2529870467","title":"BRIEF-Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2529870467","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529870467?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:50","pubTimestamp":1745236231,"startTime":"0","endTime":"0","summary":"BRIEF-Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional IndicationsApril 21 (Reuters) - Immunovant Inc IMVT.O:IMMUNOVANT ANNOUNCES NEXT PHA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA2BSGQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IMVT","BK4007","ROIV","BK4585"],"gpt_icon":0},{"id":"2529706468","title":"Immunovant CEO Salzmann Retires; Roivant Exec Venker Takes the Helm","url":"https://stock-news.laohu8.com/highlight/detail?id=2529706468","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529706468?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:44","pubTimestamp":1745235840,"startTime":"0","endTime":"0","summary":"Immunovant unveiled a series of executive changes that more closely aligns the clinical-stage immunology company with majority shareholder Roivant Sciences.Immunovant on Monday said Pete Salzmann has retired as chief executive and a director of the New York company, and that Eric Venker, a board member who also serves as Roivant's president, has stepped in as CEO.The company said Salzmann, who joined as CEO in 2019, will be eligible for severance benefits as part of a separation agreement.Immunovant also said Renee Barnett has stepped down as chief financial officer and has been succeeded by Tiago Girao, who has served as finance chief for multiple Roivant units since 2019.The company said Barnett, 45 years old, will receive an annual base salary of $481,000 and an annual bonus with a target of 45% of his base pay, adding that it expects to sign a separation agreement with Barnett that includes severance benefits.Immunovant said the executive changes are part of a broader strategic tra","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4588","ROIV","BK4007","BK4585"],"gpt_icon":0},{"id":"2529874605","title":"Immunovant Inc - Tiago Girao Appointed as CFO of Immunovant","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874605?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:00","pubTimestamp":1745233201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA2BSGQH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4585","ROIV","BK4007","BK4588"],"gpt_icon":0},{"id":"2529874152","title":"Immunovant Inc - Ind Cleared for Imvt-1402 in Sjd, Study to Initiate Summer 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874152?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:00","pubTimestamp":1745233201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA2BSGQH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4585","BK4588","BK4007","ROIV"],"gpt_icon":0},{"id":"2529492874","title":"Immunovant Inc - Current Cash Balance Provides Runway Through Graves’ Disease Readout in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2529492874","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529492874?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:00","pubTimestamp":1745233201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA2BSGQH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","ROIV","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"2529287467","title":"Immunovant Announces Next Phase of Growth With Roivant Including Changes to Its Leadership Team and Additional Indications SjÖGren’s Disease (Sjd) and Cutaneous Lupus Erythematosus (Cle) for Imvt-1402","url":"https://stock-news.laohu8.com/highlight/detail?id=2529287467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529287467?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:00","pubTimestamp":1745233201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA2BSGQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4007","IMVT","ROIV","BK4588"],"gpt_icon":0},{"id":"2522374757","title":"Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374757","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374757?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:56","pubTimestamp":1743076560,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research.Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter.Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial.Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer.Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV","ABUS"],"gpt_icon":0},{"id":"2522860768","title":"Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522860768","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522860768?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:12","pubTimestamp":1742926370,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Roivant Sciences Ltd.  stands against other best stocks to buy according to billionaire David Einhorn.David Einhorn is a highly regarded hedge fund manager, who co-foundedGreenlight Capitalin 1996. Einhorn shot to fame after he correctly forecasted the collapse of Lehman Brothers during the financial crisis. He graduated from Cornell University and garnered his skills in the hedge fund industry under the mentorship of Gary Siegler and Peter Collery at the SC Fundamental Value Fund.Due to his prowess in long/short equity strategies, David Einhorn is being tagged as one of the most successful hedge fund managers.To list the 10 Best Stocks to Buy According to Billionaire David Einhorn, we selected the top 10 stocks in Greenlight Capital’s portfolio as per its Q4 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-sciences-ltd-nasdaq-roiv-181250568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","QID","SQQQ","NDAQ","LU2210149790.SGD","BK4585","MNQmain","BK4139","IE00BKPKM429.USD","TQQQ","IMVT","BK4588","BK4112","LU2095319765.USD","QLD","NVIW.SI","LU2210150020.SGD","PSQ","TSYW.SI","BK4007","BK4019","USJW.SI","IE00B3QW5Z07.USD","ROIV","NQmain",".IXIC","USAW.SI","GLRE","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2520578321","title":"Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2520578321","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520578321?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 00:39","pubTimestamp":1742402340,"startTime":"0","endTime":"0","summary":"Wednesday, Immunovant,Inc.  released topline results from its Phase 3 study of batoclimab in myasthenia gravis  and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy .Immunovant is a member of theRoivant Sciences Ltd. family of companies.In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living  score in acetylcholine receptor antibody positive  participants.Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6-point improvement  in MG-ADL at Week 12.In comparison, those randomized to 340mg of batoclimab given weekly by subcutaneous injection achieved a 4.7-point improvement .Initial batoclimab data in 73 patients pooled across all cohorts for the run-in Period 1 of the Phase 2b CIDP study demonstrated a 1.8 point improvement in aINCAT  at Week 12.An 84% responder rate  was observed a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-ditches-seeking-fda-approval-163900373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","MG","IE00B66KJ199.SGD","ROIV","IE00B7SZL793.SGD","BK4139","BK4123","IE0031619046.USD","BK4585","BK4588","BK4007","IMVT"],"gpt_icon":0},{"id":"2520900531","title":"Roivant Sciences Ltd - Phase 3 Mg Study Meets Primary Endpoint With 5.6 Point Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2520900531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520900531?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:45","pubTimestamp":1742384700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7LCRWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2516637517","title":"Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516637517?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 23:07","pubTimestamp":1741014467,"startTime":"0","endTime":"0","summary":"Roivant Sciences'  subsidiary Genevant Sciences and Arbutus Biopharma  said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.Moderna did not i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","BK4534","BK4501","ABUS","BK4551","BK4532","BK4585","BK4139","BK4568","ROIV","BK4548","BK4007","BK4588"],"gpt_icon":1},{"id":"2516313176","title":"Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2516313176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516313176?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA4YDVCV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4548","BK4588","ROIV","BK4007","BK4568","BK4532","ABUS","BK4551","MRNA","BK4533","BK4139","BK4585","BK4501"],"gpt_icon":0},{"id":"2516631339","title":"Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631339?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA5GW9JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ROIV","ABUS"],"gpt_icon":0},{"id":"2516316566","title":"Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2516316566","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516316566?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011300,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025  -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle  patent portfolio , and Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA.Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S. and Europe indicating that the samples contain LNPs fall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genevant-sciences-arbutus-biopharma-initiate-141500465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABUS","UPC","BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2514096269","title":"Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant Announces Resignation and Replacement of Arbutus Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096269?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA66NWKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"1114746336","title":"Stock Track | Roivant Sciences Soars 5.27% After-Hours as Analysts Upgrade Financial Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1114746336","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114746336?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 06:16","pubTimestamp":1739398594,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  stock surged 5.27% in after-hours trading on Wednesday, following analysts' significant upgrades to their revenue and earnings estimates for the company.Analysts covering Roivant Sciences revised their consensus estimates, projecting $43 million in revenue for the company in 2026, a sharp increase from their previous forecast of $36 million. Additionally, they reduced their loss estimates for the next year, now expecting losses of $1.17 per share instead of the earlier pro","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Roivant Sciences Soars 5.27% After-Hours as Analysts Upgrade Financial Forecasts","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":1},{"id":"2511658162","title":"Roivant Sciences Insiders Sold US$52m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511658162","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511658162?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 19:36","pubTimestamp":1739360176,"startTime":"0","endTime":"0","summary":"Many Roivant Sciences Ltd. ( NASDAQ:ROIV ) insiders ditched their stock over the past year, which may be of interest to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-insiders-sold-us52m-of-shares-suggesting-he","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2510606327","title":"News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2510606327","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510606327?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 19:03","pubTimestamp":1739358188,"startTime":"0","endTime":"0","summary":"Celebrations may be in order for Roivant Sciences Ltd.  shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for next year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.Following the latest upgrade, the five analysts covering Roivant Sciences provided consensus estimates of US$43m revenue in 2026, which would reflect a painful 65% decline on its sales over the past 12 months. Per-share losses are expected to see a sharp uptick, reaching US$1.17. However, before this estimates update, the consensus had been expecting revenues of US$36m and US$1.19 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/news-flash-analysts-just-made-110308191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NDAQ","ROIV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roivant.com","stockEarnings":[{"period":"1week","weight":0.0358},{"period":"1month","weight":-0.0343},{"period":"3month","weight":-0.0663},{"period":"6month","weight":-0.1169},{"period":"1year","weight":-0.017},{"period":"ytd","weight":-0.1192}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.085134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004587},{"month":3,"riseRate":0,"avgChangeRate":-0.096551},{"month":4,"riseRate":0.8,"avgChangeRate":-0.003891},{"month":5,"riseRate":0.5,"avgChangeRate":0.053964},{"month":6,"riseRate":0.75,"avgChangeRate":0.012477},{"month":7,"riseRate":0.75,"avgChangeRate":0.048723},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002132},{"month":9,"riseRate":0.25,"avgChangeRate":-0.05068},{"month":10,"riseRate":0.5,"avgChangeRate":0.046516},{"month":11,"riseRate":0.75,"avgChangeRate":0.021182},{"month":12,"riseRate":0.75,"avgChangeRate":0.279121}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}